| 摘要: |
| 三阴性乳腺癌（triple negative breast cancer，TNBC）是雌激素受体（estrogen receptor，ER）孕激素受体（progesterone receptor，PR）和人表皮生长因子受体2（human epidermal growth factor receptor 2，Her-2）均表达缺失的乳腺癌，其具有自己独特的病理和分子生物学特性，与基底细胞样乳腺癌有较高的一致性。具有复发早、进展快、生存期短和预后较其他类型乳腺癌差的临床特点。此类型乳腺癌对常规放化疗不敏感。对TNBC的靶向治疗的深入研究，将有助于人们采取有效的治疗方法来提高其疗效。 |
| 关键词: 乳腺癌 三阴性 靶向治疗 |
| DOI：10.11724/jdmu.2011.02.23 |
| 分类号:R737.9 |
| 基金项目: |
|
| Research development of triple negative breast cancer targeted therapy |
|
CHENG Lei, WANG Hong-jiang
|
|
Department of General Surgery,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China
|
| Abstract: |
| Triple negative breast cancer (TNBC) is a subgroup of breast cancers,defined by a lack of the expressions of estrogen,progesterone and HER2 receptors,with its exclusive pathological and molecular biological characteristics and a close relationship with basal-like breast cancer.TNBC is associated with increased risk for distant metastases,early recurrence,short lifetime and with poorer prognosis than other type of breast cancer.TNBC is insensitive to standard radiotherapy and chemotherapy.A deeper insight into the targeted therapy of TNBC may lead to improved therapies and better clinical outcomes of the disease. |
| Key words: breast cancer triple-negative targeted therapy |
